Title

The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice

Megumi Akamatsu¹,†, Takenari Yamashita¹,†, Naoki Hirose¹, Sayaka Teramoto¹, Shin Kwak¹,²,*

¹ Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan

² Clinical Research Center for Medicine, International University of Health and Welfare, Ichikawa, Chiba, Japan

† These authors contributed equally to this work.

*Correspondence and requests should be addressed to S. K. (kwak-tky@umin.ac.jp).

Supplementary Figure 1
Supplementary Figure 1. Effects of 90-day administration of perampanel and vehicle on AHC size in AR2 mice. Frequency histogram of AHC diameter for perampanel-treated (a) and methyl cellulose-treated (b) 38-week-old AR2 mice compared to age-matched non-treated (NT) WT mice. The vertical axis indicates the proportion of the total number of AHCs with a diameter within each range. (a) The frequency peak was in the range of 30-35 µm in both the perampanel-treated AR2 and the WT mice. (b) The frequency peak for the vehicle-treated AR2 mice was in a smaller range (25-30 µm) than that for the WT mice (30-35 µm). All error bars represent the s.e.m. *p < 0.05, Wilcoxon rank sum test against WT (NT) for each diameter. The perampanel group included 8 mice, the vehicle group included 7, and the WT group included 5. AHCs were counted in three sections per mouse.